Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -414.54% is 227% below its 5-year average of -126.75%, near the low end of its 5-year range (-414.54%–-38.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 83.02% below its 12-month average of -226.50%.
Reported quarterly return on assets; no daily interpolation. Q4 FY2026 (2026-06-30): -167.81%.
RETURN ON ASSETS (ROA)
-414.54%
RETURN ON ASSETS (ROA) AVG TTM
-226.50%
RETURN ON ASSETS (ROA) AVG 3Y
-135.75%
RETURN ON ASSETS (ROA) AVG 5Y
-126.75%
RETURN ON ASSETS (ROA) AVG 10Y
-107.34%
RETURN ON ASSETS (ROA) AVG 15Y
-94.47%
RETURN ON ASSETS (ROA) AVG 20Y
-158.01%
CURRENT VS TTM AVG
-83.02%
CURRENT VS 3Y AVG
-205.38%
CURRENT VS 5Y AVG
-227.04%
CURRENT VS 10Y AVG
-286.19%
CURRENT VS 15Y AVG
-338.81%
CURRENT VS 20Y AVG
-162.35%
SECTOR MEDIAN · HEALTHCARE
-30.07%
median of 666 covered companies
CURRENT VS SECTOR MEDIAN
-1278.58%
vs the sector median at left
InMed Pharmaceuticals Inc.
Market Cap
$7.31M
Return on Assets (ROA)
-414.54%
TTM Avg
-226.50%
3Y Avg
-135.75%
5Y Avg
-126.75%
Market Cap
$7.24M
Return on Assets (ROA)
-206.32%
TTM Avg
-53.14%
3Y Avg
-33.03%
5Y Avg
-33.03%
Market Cap
$7.28M
Return on Assets (ROA)
-95.26%
TTM Avg
-176.86%
3Y Avg
-120.19%
5Y Avg
-105.02%
Market Cap
$7.43M
Return on Assets (ROA)
-151.57%
TTM Avg
-141.88%
3Y Avg
-132.44%
5Y Avg
-101.65%
Market Cap
$6.98M
Return on Assets (ROA)
-106.57%
TTM Avg
-92.47%
3Y Avg
-315.20%
5Y Avg
-267.86%
Market Cap
$7.13M
Return on Assets (ROA)
-283.63%
TTM Avg
-124.17%
3Y Avg
-74.25%
5Y Avg
-35.74%
Market Cap
$7.02M
Return on Assets (ROA)
-1082.20%
TTM Avg
-652.69%
3Y Avg
-445.69%
5Y Avg
-363.52%
Market Cap
$7.97M
Return on Assets (ROA)
-381.53%
TTM Avg
-330.40%
3Y Avg
-209.86%
5Y Avg
-253.27%
Market Cap
$7.86M
Return on Assets (ROA)
-76.12%
TTM Avg
-177.28%
3Y Avg
-394.98%
5Y Avg
-300.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $7.31M | -414.54% | -226.50% | -135.75% | -126.75% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.24M | -206.32% | -53.14% | -33.03% | -33.03% |
| KALA BIO, Inc. (KALA)vs › | $7.28M | -95.26% | -176.86% | -120.19% | -105.02% |
| Longeveron Inc. (LGVN)vs › | $7.43M | -151.57% | -141.88% | -132.44% | -101.65% |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -106.57% | -92.47% | -315.20% | -267.86% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -283.63% | -124.17% | -74.25% | -35.74% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | -1082.20% | -652.69% | -445.69% | -363.52% |
| GT Biopharma, Inc. (GTBP)vs › | $7.97M | -381.53% | -330.40% | -209.86% | -253.27% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.86M | -76.12% | -177.28% | -394.98% | -300.85% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $8.00M | -74.50% | -220.41% | -182.97% | -158.82% |
ROA
-414.5%
ROE
-1168.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-06-30 | -414.54% |
| 2025-06-30 | -38.45% |
| 2024-06-30 | -47.47% |
| 2023-06-30 | -42.53% |
| 2022-06-30 | -112.97% |
| 2021-06-30 | -104.57% |
| 2020-06-30 | -114.57% |
| 2019-06-30 | -66.41% |
| 2018-06-30 | -41.64% |
| 2017-06-30 | -53.67% |
| 2016-06-30 | -143.92% |
| 2015-06-30 | -258.45% |
| 2014-06-30 | -72.47% |
| 2013-06-30 | -917.49% |
| 2012-06-30 | -401.45% |
| 2011-06-30 | -130.97% |
| 2010-06-30 | -231.34% |
| 2009-06-30 | -4169.14% |
| 2008-06-30 | -66.78% |
| 2007-06-30 | -464.76% |
| 2006-06-30 | -195.26% |
| 2005-06-30 | -282.17% |
| 2004-07-31 | -278.42% |
| 2003-07-31 | -105.72% |
| 2002-07-31 | -198.98% |
| 2001-07-31 | -91.36% |
